Sign In
Buy ATAI
$4.53
-0.280 (-5.82%)
At Close: Jun 03, 2026
atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference
07:00am, Friday, 31'st May 2024
NEW YORK and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of
atai Life Sciences bolsters board with two new directors
08:11am, Thursday, 23'rd May 2024
atai Life Sciences has announced the appointments of Scott Braunstein and Laurent Fischer as directors to its board. Braunstein previously served as chief operating officer of Pacira Pharmaceuticals a
atai Life Sciences poised to create value as psychedelic therapies gain traction, analysts believe
11:32am, Thursday, 16'th May 2024
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has a pipeline of psychedelic and non-psychedelic drug assets that are poised to create value, analysts at Jefferies believe. “We think atai's pipeline of p
atai Life Sciences boss makes way for co-founder on better first quarter
09:04am, Wednesday, 15'th May 2024
atai Life Sciences has announced Florian Brand will step down as chief executive and be succeeded by co-founder Srinivas Rao. Rao, who currently serves as the biopharmaceutical firm's chief scientific
atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates
06:59am, Wednesday, 15'th May 2024
NEW YORK and BERLIN, May 15, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of
atai Life Sciences investee Beckey Psytech starts dosing patients in second part of treatment-resistant depression study
08:48am, Wednesday, 24'th Apr 2024
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that Beckley Psytech has dosed the first patient in the second part of its Phase 2a study of its novel intranasal 5-MeO-MDT drug candidate BPL-003 i
NEW YORK and BERLIN, April 24, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment o
Arecor Therapeutics: Bank sees huge potential
09:58am, Monday, 22'nd Apr 2024
In a bullish endorsement for Arecor Therapeutics PLC (AIM:AREC), Panmure Gordon has issued a 'buy' recommendation, underpinning a significant upside potential with a target price of 539p — over four
atai announces publication of Beckley Psytech's Phase 1 study for novel 5-MeO-DMT asset
09:16am, Wednesday, 17'th Apr 2024
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that the results of investee Beckley Beckley Psytech's Phase 1 study of its novel, novel, synthetic, intranasal benzoate salt formulation of 5-MeO-D
atai Life Sciences Announces the Publication of Beckley Psytech's Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
07:00am, Wednesday, 17'th Apr 2024
NEW YORK and BERLIN, April 17, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment o
atai Life Sciences CEO Florian Brand spotlights psychedelic therapy milestones and upcoming catalysts
04:22pm, Monday, 15'th Apr 2024
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) made significant strides in advancing its innovative mental health therapies in 2023, with a focus on psychedelic-based treatments for depression. CEO and
Are You Looking for a Top Momentum Pick? Why atai Life Sciences N.V.
01:02pm, Thursday, 04'th Apr 2024
Does atai Life Sciences N.V. (ATAI) have what it takes to be a top stock pick for momentum investors?
atai Life Sciences funded into 2026; sets sights on key milestones for its psychedelic therapies
08:45am, Thursday, 28'th Mar 2024
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) said it has enough cash, marketable securities, and a committed loan facility to support its operations into 2026 as it continues to advance psychedelic-based
atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights
07:00am, Thursday, 28'th Mar 2024
NEW YORK and BERLIN, March 28, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”) a clinical-stage biopharmaceutical company aiming to transform the treatment o
atai-backed Beckley Psytech unveils positive results from DMT for treatment-resistant depression study
08:40am, Wednesday, 27'th Mar 2024
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has hailed positive results from its investee Beckley Psytech's Phase 2a study of its novel DMT formulation BPL-003 in patients with treatment-resistant depre
